Ascendis Pharma A/S Revenue and Competitors

Hellerup, Denmark



Total Funding



Estimated Revenue & Valuation

  • Ascendis Pharma A/S's estimated annual revenue is currently $3.4M per year.(i)
  • Ascendis Pharma A/S received $115.0M in venture funding in October 2016.
  • Ascendis Pharma A/S's estimated revenue per employee is $3,118
  • Ascendis Pharma A/S's total funding is $85.7M.
  • Ascendis Pharma A/S's current valuation is $7B. (January 2022)

Employee Data

  • Ascendis Pharma A/S has 1097 Employees.(i)
  • Ascendis Pharma A/S grew their employee count by -1% last year.

Ascendis Pharma A/S's People

Director, Analytical DevelopmentReveal Email/Phone
Associate Director, Site Contracts & BudgetsReveal Email/Phone
Director BiostatisticsReveal Email/Phone
Senior Manager, Medical InformationReveal Email/Phone
Regional Medical ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

What Is Ascendis Pharma A/S?

Ascendis Pharma is a biotechnology company applying its innovative prodrug technology to build a leading, fully integrated rare disease company. Our science-driven and passionate people are advancing a pipeline of endocrinology programs focused on making a difference in patients lives. By utilizing our TransCon technology with clinically validated parent drugs, we create new therapies with potential for best-in-class efficacy, safety and/or convenience. Ascendis Pharma is headquartered in Copenhagen, Denmark, maintains an office in Palo Alto, California, and has research and development facilities in Heidelberg, Germany, and Copenhagen, Denmark.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Ascendis Pharma A/S News

2022-04-19 - Is Ascendis Pharma A/S (ASND) Stock About to Get Hot Friday?

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet...

2022-04-17 - Ascendis Pharma A/S (NASDAQ:ASND) Receives $184.78 ...

Ascendis Pharma A/S (NASDAQ:ASND) Receives $184.78 Consensus PT from Analysts. Posted by admin on Apr 18th, 2022.

2022-03-22 - Ascendis Pharma Prices US$500.0 Million Convertible Senior ...

Ascendis Pharma also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and...

2021-11-19 - Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward Trial Demonstrating that TransCon™ PTH Provided Durable Benefit and Was Well-Tolerated in Adults with Hypoparathyroidism

–– 58 of the original 59 subjects continue in the open-label extension portion of the Phase 2 trial. –– Phase 3 data for TransCon PTH expected in Q1 2022. COPENHAGEN, Denmark, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced top-line results from Week 84 of ...

2021-11-11 - Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results - Form 6-K

Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results - SKYTROFA® (lonapegsomatropin-tcgd) approved by the FDA in the U.S. as a once-weekly treatment for pediatric growth hormone deficiency (GHD); commercially launched in October 2021. - Completed enrollment in Phase 3 PaTHway Trial ...

Ascendis Pharma A/S Funding

DateAmountRoundLead InvestorsReference
2016-10-19$115.0MUndisclosedJ.P. Morgan Securities LLC,Article